Protocol summary

Study aim
The effect of magnesium supplement as adjunctive therapy to methylphenidate in patients with attention deficit hyperactivity disorder
Design
Randomized, double-blind, placebo controlled clinical trial
Settings and conduct
The participants in the study are selected from among the referrals to Ziaeian Hospital based on inclusion criteria. Diagnosis of ADHD is performed by a child and adolescent psychiatrist.The total number of samples is 62 patients. Patients will be divided randomly in two group of 31 patients. The first group will receive methylphenidate and magnesium, the second group will receive methylphenidate and placebo, for 8 weeks. Patients are evaluated before intervention, 4 and 8 weeks after intervention. The severity of the symptoms is evaluated by the Conner's Rating Scale questionnaire of parents and ADHD Rating Scale. Side effects will be recorded in 4 and 8 weeks after the intervention.
Participants/Inclusion and exclusion criteria
Inclusion criteria: 1-Age between 8-16 years old 2-Diagnosis of ADHD by the pediatric psychiatrist 3-Lack of mental retardation 4-No history of epilepsy and seizure 5-Intake methylphenidate tablet as the main method of drug therapy 6-consent of the patient and parents to participate in the research. Exclusion criteria: 1-Renal failure 2-intolerance to magnesium
Intervention groups
The first group received methylphenidate and magnesium at a dose of 125 mg/day for patients less than 35 kg and 250 mg/day for patients more than 35 kg.The second group received methylphenidate and placebo.
Main outcome variables
Decrease attention deficit, hyperactivity symptoms

General information

Reason for update
Acronym
ADHD
IRCT registration information
IRCT registration number: IRCT20160813029327N19
Registration date: 2020-09-07, 1399/06/17
Registration timing: retrospective

Last update: 2020-09-07, 1399/06/17
Update count: 0
Registration date
2020-09-07, 1399/06/17
Registrant information
Name
Ramin Abrishami
Name of organization / entity
Islamic Azad University, Pharamceutical sciences branch
Country
Iran (Islamic Republic of)
Phone
+98 21 2264 1889
Email address
r_abrishami@iaups.ac.ir
Recruitment status
Recruitment complete
Funding source
Expected recruitment start date
2018-08-06, 1397/05/15
Expected recruitment end date
2019-07-06, 1398/04/15
Actual recruitment start date
empty
Actual recruitment end date
empty
Trial completion date
empty
Scientific title
Evaluation of the efficacy of the methylphenidate in combination with magnesium and methylphenidate with placebo in patients with attention deficit hyperactivity disorder
Public title
The effect of magnesium in patients with attention deficit hyperactivity disorder
Purpose
Treatment
Inclusion/Exclusion criteria
Inclusion criteria:
Age between 8-16 years old Diagnosis of ADHD by the pediatric psychiatrist Lack of mental retardation No history of epilepsy and seizure Intake methylphenidate tablet as the main method of drug therapy Consent of the patient and parents to participate in the research
Exclusion criteria:
Renal failure intolerance to magnesium
Age
From 8 years old to 16 years old
Gender
Both
Phase
3
Groups that have been masked
  • Participant
  • Care provider
  • Data analyser
Sample size
Target sample size: 62
Randomization (investigator's opinion)
Randomized
Randomization description
block randomization
Blinding (investigator's opinion)
Double blinded
Blinding description
Patients and physician will be blind about drug
Placebo
Used
Assignment
Parallel
Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee
Name of ethics committee
Ethics committee of Islamic Azad University of Pharmaceutical Sciences
Street address
#99, The First of Yakhchal Ave., Gholhak, Shariati St.
City
Tehran
Province
Tehran
Postal code
19395-6466
Approval date
2018-03-03, 1396/12/12
Ethics committee reference number
IR.IAU.PS.REC.1396.236

Health conditions studied

1

Description of health condition studied
Attention deficit hyperactivity disorder
ICD-10 code
F90
ICD-10 code description
Attention-deficit hyperactivity disorders

Primary outcomes

1

Description
Scores in Conner's Parent Rating Scale questionnaire
Timepoint
Before, 4 weeks and 8 weeks after intervention
Method of measurement
Conner's Parent Rating Scale questionnaire

2

Description
Scores in ADHD Rating Scale questionnaire
Timepoint
Before, 4 weeks and 8 weeks after intervention
Method of measurement
ADHD Rating Scale questionnaire

Secondary outcomes

empty

Intervention groups

1

Description
Intervention group: patients will receive 0.3 to 2 mg/kg/day methylphenidate tablet and magnesium at a dose of 125 mg/day for patients less than 35 kg and 250 mg/day for patients more than 35 kg for 8 weeks.
Category
Treatment - Drugs

2

Description
Control group: patients will receive 0.3 to 2 mg/kg/day methylphenidate tablet and placebo for 8 weeks
Category
Placebo

Recruitment centers

1

Recruitment center
Name of recruitment center
Ziaeian hospital
Full name of responsible person
Fatemeh Ajorloo
Street address
Abouzar St, District 17, Tehran, Iran
City
Tehran
Province
Tehran
Postal code
1366736511
Phone
+98 21 5517 6810
Email
fateme.ajorloo@gmail.com

Sponsors / Funding sources

1

Sponsor
Name of organization / entity
Islamic Azad University
Full name of responsible person
Farshad Hashemian
Street address
Yakhchal St, Shariati St.
City
Tehran
Province
Tehran
Postal code
19395-6466
Phone
+98 21 2264 0051
Email
fhashemian@yahoo.com
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
Yes
Title of funding source
Islamic Azad University
Proportion provided by this source
100
Public or private sector
Public
Domestic or foreign origin
Domestic
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
Academic

Person responsible for general inquiries

Contact
Name of organization / entity
Islamic Azad University
Full name of responsible person
Ramin Abrishami
Position
Assistant professor
Latest degree
Specialist
Other areas of specialty/work
Medical Pharmacy
Street address
#99, the first of Yakhchal Ave., Gholhak, Shariati St.
City
Tehran
Province
Tehran
Postal code
193956466
Phone
+98 21 2264 0051
Email
r_abrishami@iaups.ac.ir

Person responsible for scientific inquiries

Contact
Name of organization / entity
Tehran University of Medical Sciences
Full name of responsible person
Mohammad Effatpanah
Position
Assistant Professor
Latest degree
Subspecialist
Other areas of specialty/work
Psychiatrics
Street address
Enghelab avenue, Tehran University of Medical Sciences.
City
Tehran
Province
Tehran
Postal code
1417653761
Phone
+98 21 2264 0051
Email
m.effatpanah@gmail.com

Person responsible for updating data

Contact
Name of organization / entity
Islamic Azad University
Full name of responsible person
Ramin Abrishami
Position
Assistant professor
Latest degree
Specialist
Other areas of specialty/work
Medical Pharmacy
Street address
#99, Yakhchal Ave., Shariati st.
City
Tehran
Province
Tehran
Postal code
193956466
Phone
+98 21 2264 0051
Email
r_abrishami@iaups.ac.ir

Sharing plan

Deidentified Individual Participant Data Set (IPD)
Undecided - It is not yet known if there will be a plan to make this available
Study Protocol
No - There is not a plan to make this available
Statistical Analysis Plan
Undecided - It is not yet known if there will be a plan to make this available
Informed Consent Form
No - There is not a plan to make this available
Clinical Study Report
No - There is not a plan to make this available
Analytic Code
No - There is not a plan to make this available
Data Dictionary
No - There is not a plan to make this available
Loading...